As of July 8, 2013 - protocols do open and close daily.
Please check with your physician for additional protocols and/or information.
1. E1411: Intergroup Randomized Phase 2 Four Arm Study in Patients >/= 60 with Previously Untreated Mantle Cell Lymphoma of Therapy with: Arm A = Rituximab+Bendamustine Followed by Rituximab Consolidation (RB -->R); Arm B = Rituximab+Bendamustine+Bortezomib Followed By Rituximab Consolidation (RBV--> R), Arm C = Rituximab+Bendamustine Followed by Lenalidomide+Rituximab Consolidation (RB --> LR) or Arm D = Rituximab+Bendamustine+Bortezomib Followed by Lenalidomide+Rituximab Consolidation (RBV --> LR)
The purpose of this study is two fold and has two steps of treatment:
1) In step 1, to find out what effects, good and bad, the addition of bortezomib to rituximab plus bendamustine has on you and your lymphoma compared to rituximab plus bendamustine alone.
2) In step 2, to find out what effects, good and bad, continuing treatment after step 1 with lenalidomide plus rituximab has on you and your lymphoma compared to continuing treatment with rituximab alone.
For more information on these protocols or any other research, please contact your physician or our clinical research coordinator, Jessica Gerlach, CCRP at 845-333-1133